- €116.31m
- €386.34m
- €786.44m
Brief: Guerbet Confirms Financial Targets For 2023 And 2024
Brief: Guerbet H1 Net Income Down At EUR 1.3 Million
Brief: Guerbet 2023 Half-Year Results
Brief: Guerbet H1 Revenue At EUR 378.6 Million
Brief: Guerbet Announces Results Of Reopened Public Tender Offer For Intrasense Shares
Brief: Guerbet Appoints Didier Izabel As Chair Of Board Of Directors
Hold!! French And Benelux Stocks: Factors to watch
Brief: Guerbet Announces Positive Outcome Of Tender Offer For Intrasense Shares
Brief: Guerbet Announces ACR Committee Classified Elucirem Injection A Group II Agent
Brief: Guerbet Confirms 2023 And 2024 Objectives
Brief: Guerbet SA FY Revenue Eur 753.3 MLN
Brief: Guerbet Annual Revenue Up At EUR 753.3 Mln
Brief: Guerbet Announces 2023 Strategic Priorities
Brief: Intrasense Opens Its Capital To The Guerbet Group
Brief: Guerbet Q3 Revenue Up At EUR 187 Mln
Brief: Guerbet Gets EUR 1 Mln Of Public Funding From Bpifrance
Brief: Guerbet Announces FDA Approval Of Elucirem™ (Gadopiclenol)
Brief: Guerbet H1 EBITDA Down At EUR 50.5 Mln
Brief: Guerbet H1 Sales Rise To EUR 371.1 Million